11:30-12:20 Laboratory and Research Session
Detailed program on page 4

12:00-13:00 Session 9: The Current and Future of MM Care
Moderators: Moshe Gatt, Merav Leiba
12:00-12:20 Critical questions for the next decade in MM- is there a cure? Jesus San Miguel
12:20-13:00 The current and future of MM care, panel discussion and audience questions
Case presentation: Efrat Luttwak, Eyal Lebel, Phillipe Moreau, Jesus San Miguel, Dina Ben Yehuda

13:00-13:10 Concluding remarks
13:10 Lunch

Session held in Oren 1 Hall

10:00-11:30 Nursing Forum
Main theme: Moshe Gatt
10:00-10:20 Genes/biotype monitoring for hematological diseases
Moderator: Eyal Lebel
10:20-11:30 Case presentation
Moderator: Michal Cipok
10:20-11:00 Case presentation: Efrat Luttwak, Eyal Lebel, Phillipe Moreau, Jesus San Miguel, Dina Ben Yehuda
11:00-11:30 Case presentation: Efrat Luttwak, Eyal Lebel, Phillipe Moreau, Jesus San Miguel, Dina Ben Yehuda

11:30-12:20 Laboratory and research session
Moderator: Michal Cipok
11:30-11:50 Towards selective targeting of the multiple myeloma-mesenchymal stem cells’ crosstalk
Liat Drucker
11:50-12:00 FROM MM TO? (CASE NO. 201033246)
Ety Shaoul
12:00-12:10 Therapeutic antibody as a pitfall for identification of endogenous monoclonal proteins – Gabriel Bryk
12:10-12:20 Effects of Daratumumab on Pre-Transfusion Testing – Anna Feldman

www.imsregional2019.com
Thursday, February 21, 2019

08:00-08:30 Gathering

08:30-08:45 Greetings – Israel Society of Hematology
The history of Myeloma
Moshe Mittleman, Chairman, Israel Society of Hematology

08:45-08:50 Greetings – Israeli Myeloma Study Group

Moshe Gatt, Chairman, Israel Myeloma Society

08:50-09:05 IMS and IMW Introduction
Jesus San Miguel, Chairman, International Myeloma Society

09:05-09:10 Opening of Conference
Merav Leiba, Secretary, Israel Myeloma Society

08:30-09:10 Session 1: Myeloma Early Disease

Moderators: Merav Leiba, Yaacov Rowe

09:10-09:40 Keynote Lecture: From bench to bedside, future targets for the treatment of MM
Kenneth Anderson

09:40-10:00 Myeloma molecular basics / Precursor Disease States
Irene Ghobriel

10:00-10:20 SMM. Is it time to treat?
Irene Ghobriel

10:20-10:40 Case presentations roundtable and local practice
Case presentation: Chezi Ganzel
Irene Ghobriel, Kenneth Anderson, Moshe Mittleman

10:40-11:00 Coffee Break

11:00-12:20 Session 2: Induction Therapy

Moderators: Noa Lavi, Adrian Duek

11:00-11:20 Induction therapy for transplant eligible
Phillippe Moreau

11:20-11:40 Induction therapy for transplant ineligible Meletios-Athanasios Dimopoulos

11:40-12:00 MRD
Jesus San Miguel

12:00-12:20 Case presentations roundtable and local practice
Case presentation: Noa Lavi
Jesus San Miguel, Meletios-Athanasios Dimopoulos, Phillippe Moreau, Tamar Tadmor

12:20-13:00 Case presentations Transplantation Controversies – 0/1/2
Case presentation: Osnat Jarchovsky
Phillippe Moreau – YES
Paul Richardson – NO

13:00-13:20 Consolidation and Maintenance therapy
Paul Richardson

13:20-14:20 Lunch Break + POSTER SESSION

14:20-16:10 Session 4: Relapsed Disease

Moderators: Uri Abadi, Najib Dalí

14:20-14:50 First to tenth relapse
Paul Richardson

14:50-15:10 High risk disease
Merav Leiba

15:10-15:30 Primary refractory patients – The KyDaR Study
Yael Cohen

15:30-15:50 Treatment of relapsed disease outside clinical trials
Moshe Gatt

15:50-16:10 Case presentations roundtable and local practice
Case presentation: Eyal Lebel, Tamar Tadmor
Paul Richardson, Moshe Gatt, Yael Cohen, Hila Magen

16:10-16:30 Coffee Break

16:30-17:30 Session 5: Immunotherapy

Moderators: Katrin Hertzog, Ofer Shpilberg

16:30-17:10 Immunotherapy and CART
Kenneth Anderson

17:10-17:30 Case presentations roundtable and local practice
Case presentation: Adrian Duek
Kenneth Anderson, Iril Avivi

17:30-18:30 POSTER SESSION

Friday, February 22, 2019

08:00-08:30 Gathering

08:30-08:50 Blood Disease

Evanologos Terpos

08:50-09:10 Renal care

Evangelos Terpos

08:00-08:30 Session 6: Myeloma Special Care

Moderators: Celia Surio, Chezi Ganzel

08:30-08:50 Oral presentations of selected posters

High-dimensional immunophenotypic and signaling heterogeneity in multiple myeloma
Jana Jakubikova

Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4 enriched microvesicles.
Mahmood Dahab

Optimal Washout Period Between Bortezomib Induction and Stem Cell Mobilization in Patients with Multiple Myeloma – a Single Center Historical Prospective Analysis
Efrat Luttwak

In vitro anti-myeloma activity of CBD, THC enriched extracts and combinations thereof
Gabriela Rozic

Pre-treatment BDNF Protein Levels as Potential Biomarker for Response to Treatment and Peripheral Neuropathy development in Bortezomib-treated Multiple Myeloma Patients
Netanel Horowitz

Real-Life Data on the Outcome of Daratumomab-Refactory Myeloma Patients: Multi-Center Experience
Noa Lavi

10:40-11:00 Coffee Break

11:00-12:00 Session 7: Waldenstrom Macroglobulinemia

Moderators: Gilad Itzhaki, Pia Raanani

11:00-11:40 Waldenstrom Macroglobulinemia
Steve Treon

11:40-12:00 Case presentations roundtable and local practice
Case presentation: Noa Lavi
Waldenstrom Macroglobulinemia
Steve Treon, Ariel Avivi

12:00-12:20 Case presentations roundtable and local practice
Case presentation: Noa Lavi
Waldenstrom Macroglobulinemia
Steve Treon, Ariel Avivi

12:20-13:00 Case presentations Transplantation Controversies – 0/1/2
Case presentation: Osnat Jarchovsky
Phillippe Moreau – YES
Paul Richardson – NO

13:00-13:20 Consolidation and Maintenance therapy
Paul Richardson

13:20-14:20 Lunch Break + POSTER SESSION

14:20-16:10 Session 4: Relapsed Disease

Moderators: Uri Abadi, Najib Dalí

14:20-14:50 First to tenth relapse
Paul Richardson

14:50-15:10 High risk disease
Merav Leiba

15:10-15:30 Primary refractory patients – The KyDaR Study
Yael Cohen

15:30-15:50 Treatment of relapsed disease outside clinical trials
Moshe Gatt

15:50-16:10 Case presentations roundtable and local practice
Case presentation: Eyal Lebel, Tamar Tadmor
Paul Richardson, Moshe Gatt, Merav Leiba, Yael Cohen, Hila Magen

16:10-16:30 Coffee Break

16:30-17:30 Session 5: Immunotherapy

Moderators: Katrin Hertzog, Ofer Shpilberg

16:30-17:10 Immunotherapy and CART
Kenneth Anderson

17:10-17:30 Case presentations roundtable and local practice
Case presentation: Adrian Duek
Kenneth Anderson, Iril Avivi